Cephalexin Dosing for Wound Infections
For adults with wound infections, cephalexin 500 mg four times daily (QID) is the standard dose, while children should receive 25-50 mg/kg/day divided into four doses, with consideration for twice-daily dosing (BID) to improve adherence. 1
Adult Dosing
Standard Dosing
- Mild to moderate skin and soft tissue infections: 500 mg QID (every 6 hours) orally 2, 1
- Alternative regimen: 500 mg every 12 hours (BID) for uncomplicated skin infections 1
- Severe infections: Doses may be doubled, though if >4 g/day is required, parenteral cephalosporins should be considered 1
The FDA label explicitly states that 500 mg every 12 hours is acceptable for skin and skin structure infections 1, and emerging evidence supports BID dosing for improved adherence without compromising efficacy 3, 4.
Renal Dose Adjustments
Patients with creatinine clearance <30 mL/min require dose reduction proportional to their reduced renal function 5, 6. While the FDA label doesn't provide specific adjustment tables, cephalexin is 70-100% renally excreted within 6-8 hours 5. In anephric patients, single doses produce high, prolonged serum concentrations, necessitating significant dose reduction 6.
Pediatric Dosing
Standard Weight-Based Dosing
- Usual dose: 25-50 mg/kg/day divided into 4 doses (QID) 1
- For skin infections: Total daily dose may be divided every 12 hours (BID) in children >1 year 1
- Severe infections: Dosage may be doubled 1
Practical Dosing by Weight (QID regimen):
Using 250 mg/5 mL suspension 1:
- 10 kg (22 lb): 1/2 to 1 tsp QID
- 20 kg (44 lb): 1 to 2 tsp QID
- 40 kg (88 lb): 2 to 4 tsp QID
Alternative BID Regimen (Improved Adherence):
Recent pharmacokinetic modeling supports less frequent dosing 3:
- For MSSA with MIC 1-2 mg/L: 22-45 mg/kg/dose BID
- For MSSA with MIC 4 mg/L: 80 mg/kg/dose BID
High-dose TID regimen (45 mg/kg/dose, maximum 1.5 g TID) has demonstrated 99% cure rates in bone and joint infections with good tolerability 7, though this is higher than standard wound infection dosing.
Clinical Context and Guideline Framework
The 2014 IDSA guidelines position cephalexin as appropriate for methicillin-susceptible Staphylococcus aureus (MSSA) skin and soft tissue infections 2. It's specifically recommended for penicillin-allergic patients except those with immediate hypersensitivity reactions 2.
Key Considerations:
- Duration: Typically 7-10 days for skin infections 2
- MRSA coverage: Cephalexin does NOT cover MRSA; if suspected, alternative agents (trimethoprim-sulfamethoxazole, doxycycline, clindamycin) are needed 2
- Wound type matters: For animal bites, amoxicillin-clavulanate is preferred over cephalexin due to better anaerobic coverage 2, 8
Common Pitfalls:
- Don't use cephalexin for necrotizing infections - these require broader coverage with agents like piperacillin-tazobactam plus clindamycin 2
- Avoid in patients with immediate penicillin hypersensitivity - cross-reactivity risk exists 2
- Remember renal adjustment - failure to reduce dose in renal impairment can lead to accumulation 5, 6
Adherence Optimization:
BID dosing significantly improves adherence compared to QID without compromising efficacy 3, 4, 9. A pilot RCT showed high-dose cephalexin (1000 mg QID) had fewer treatment failures (3.2%) versus standard dose (12.9%), though with more minor adverse effects 4. For pediatric patients, BID or TID regimens reduce medication burden and improve compliance 3, 7.
The WHO Essential Medicines list includes cephalexin as a first-choice agent for mild skin infections alongside amoxicillin-clavulanate 8, reinforcing its role as a foundational antibiotic for wound management when MSSA is the likely pathogen.